Overview
Transplant solutions firm's Q4 revenue rose 25% yr/yr
Adjusted EPS for Q4 missed analyst expectations
Company repurchased $12 mln worth of shares during Q4
Outlook
CareDx expects full-year 2026 revenue between $420 mln and $444 mln
Company anticipates 2026 adjusted EBITDA between $30 mln and $45 mln
CareDx estimates $7.5 mln impact from Medicare LCD in 2026
Result Drivers
TESTING SERVICES GROWTH - Testing services revenue increased 23% year-over-year, driven by a 17% rise in testing volume
PATIENT AND DIGITAL SOLUTIONS - Revenue from patient and digital solutions grew 47% year-over-year, reflecting strong demand
Company press release: ID:nBw12HmWda
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted EPS | Miss | $0.12 | $0.24 (7 Analysts) |
Q4 EPS | -$0.08 | ||
Q4 Adjusted Net Income | Miss | $6 mln | $12.27 mln (6 Analysts) |
Q4 Net Income | -$4 mln | ||
Q4 Adjusted EBITDA | Miss | $7 mln | $12.60 mln (6 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CareDx Inc is $25.50, about 35.7% above its February 23 closing price of $18.79
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)